| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Blueprint for Transparency at the U.S. Food and Drug Administration: Recommendations to Advance the Development of Safe and Effective Medical Products
|
Sharfstein, Joshua M.
|
|
2017
|
45 |
2_suppl |
p. 7-23
|
artikel
|
| 2 |
Clinical Trial Transparency: The FDA Should and Can Do More
|
Kapczynski, Amy
|
|
2017
|
45 |
2_suppl |
p. 33-38
|
artikel
|
| 3 |
Disclose Data Publicly, without Restriction
|
Doshi, Peter
|
|
2017
|
45 |
2_suppl |
p. 42-45
|
artikel
|
| 4 |
FDA and the Marketplace of Ideas for Medical Products
|
Cortez, Nathan
|
|
2017
|
45 |
2_suppl |
p. 39-41
|
artikel
|
| 5 |
FDA Transparency in an Inescapably Political World
|
Carpenter, Daniel
|
|
2017
|
45 |
2_suppl |
p. 29-32
|
artikel
|
| 6 |
Introduction
|
Davis, Anna L.
|
|
2017
|
45 |
2_suppl |
p. 5-6
|
artikel
|
| 7 |
Letter from the Editor
|
McClellan, Courtney
|
|
2017
|
45 |
2_suppl |
p. 1
|
artikel
|
| 8 |
Transparency at the U.S. Food and Drug Administration
|
Califf, Robert M.
|
|
2017
|
45 |
2_suppl |
p. 24-28
|
artikel
|
| 9 |
Withholding Information on Unapproved Drug Marketing Applications: The Public Has a Right to Know
|
Almashat, Sammy
|
|
2017
|
45 |
2_suppl |
p. 46-49
|
artikel
|
Tijdschrift beschrijving